Focus on implantation of artificial discs to treat degenerative disc disease

NewsGuard 100/100 Score
Implantation of artificial discs to treat degenerative disc disease was the subject of multiple presentations earlier this month at the Spine Arthroplasty Meeting in Vienna, Austria, where spine and orthopaedic surgeons from all over the world heard new data about this technology. "This is a very hot topic," said Scott Blumenthal, M.D, an orthopaedic spine surgeon from the Texas Back Institute in Plano, who presented data from the CHARITÉ™ Artificial Disc U.S. clinical trial. "Doctors have a tremendous interest in artificial disc technology."

The CHARITÉ™ Artificial Disc was the subject of 12 presentations at the meeting. Presentations included data discussing safety, efficacy, range of motion, disc height, biomechanics, disc placement, radiological results and patient outcomes.

The CHARITÉ™ Artificial Disc is currently under review by the U.S. Food and Drug Administration (FDA) and will be the subject of an FDA Advisory Committee meeting on June 2, 2004.

Implantation of artificial discs may provide an alternative to lumbar spinal fusion surgery, a procedure that helps reduce back pain, but limits a patient’s range of motion and may unnaturally stress adjacent anatomy. Lumbar spinal fusion surgery is performed on more than 200,000 people each year in the United States.

The CHARITÉ™ Artificial Disc is made of two metal endplates and a polyethylene core that allows for motion and function very much like a normal disc. Currently, the CHARITÉ™ Artificial Disc is a medical device limited by U.S. (Federal) law to investigational use within the United States. It is available in more than 30 countries throughout the world.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals lifestyle factors boosting IVF success